Evaxion A/S (EVAX) Stock: Buy, Sell, or Hold?
EVAX - Evaxion A/S American Depositary Share
$3.20
0.02 (0.63%)
â˛
5d:
-4.19%
30d:
+4.23%
90d:
-5.33%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 19, 2026
Get Alerted When EVAX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: EVAX is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: EVAX is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: EVAX is currently trading at $3.20, which is considered fair relative to its 30-day fair value range of $3.06 to $3.27. From a valuation perspective, the stock is trading at a discount (Forward PE: -213.3) compared to its historical average (83.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, EVAX is in a strong downtrend. The price is currently testing key support at $3.13. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: EVAX scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EVAX is in a strong downtrend. The price is currently testing key support at $3.13. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: EVAX scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$3.06 -
$3.27
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (38/100)
- BULLISH: High volume confirmation
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 38/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.06 -
$3.27
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$3.13
Resistance Level
$3.35
Current Trend
Strong Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-213.33
Revenue Growth (YoY)
-100.0%
Profit Margin
-115.5%
PE vs Historical
-213.3 vs 83.6
CHEAP
Share & Embed Analysis
Last updated: October 04, 2026 4:56 AM ET
Data refreshes hourly during market hours. Next update: 5:56 AM
Data refreshes hourly during market hours. Next update: 5:56 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EVAX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 49 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 52 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$47 | 46 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$139 | 55 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$118 | 55 HOLD |